PMID- 23924450
OWN - NLM
STAT- MEDLINE
DCOM- 20140321
LR  - 20181202
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 126
IP  - 15
DP  - 2013
TI  - Evaluation of efficacy and safety of sunitinib regimen in 22 patients with 
      metastatic renal cell carcinoma: at least 12-month follow-up.
PG  - 2826-9
AB  - BACKGROUND: Sunitinib has been proved an effective new option for treatment of 
      metastatic renal cell carcinoma (mRCC). Analysis of clinical data of 22 patients, 
      who were exposed to sunitinib for at least 1 year, was conducted to evaluate the 
      long-term efficacy and safety of sunitinib for the treatment of mRCC. METHODS: A 
      total of 54 patients with mRCC were treated with sunitinib malate, 50 mg/d 
      orally, on a 4-weeks-on and 2-weeks-off dosing schedule in Peking University 
      First Hospital. Treatment continued until disease progression, unacceptable 
      adverse events (AEs), or death. Among them, 22 patients continued treatment for 
      at least 1 year. The clinical data of these 22 patients were prospectively 
      collected for analysis. AEs were assessed according to the National Cancer 
      Institute Common Terminology Criteria for Adverse Events, Version 3.0. Tumor 
      response was evaluated in accordance with the Response Evaluation Criteria in 
      Solid Tumors. RESULTS: Median progression-free survival was 19.5 months until 
      last follow-up. The best efficacy results achieved were complete response, 
      partial response, and stable disease for 2, 9, and 11 patients, respectively. 
      Objective response rate was 50%. The most common AEs were hand-foot syndrome 
      (95%) and hypertension (91%). Other common AEs were thyroid-stimulating hormone 
      elevation (82%), platelet decrease (77%), and loss of appetite (77%). Only one 
      patient withdrew from treatment for cardiac infarction. Another nine patients 
      experienced dose modifications or short-term suspensions. CONCLUSION: Long-term 
      exposure to sunitinib malate showed encouraging efficacy in the treatment of 
      mRCC. At the same time, the tolerability was good.
FAU - Zhang, Cui-jian
AU  - Zhang CJ
AD  - Department of Urology, Peking University First Hospital, Beijing 100034, China.
FAU - Zhao, Peng-ju
AU  - Zhao PJ
FAU - Li, Xue-song
AU  - Li XS
FAU - Zhao, Jing
AU  - Zhao J
FAU - Huang, Li-hua
AU  - Huang LH
FAU - Song, Yi
AU  - Song Y
FAU - Gong, Kan
AU  - Gong K
FAU - Shen, Cheng
AU  - Shen C
FAU - Yu, Wei
AU  - Yu W
FAU - Song, Gang
AU  - Song G
FAU - Zhao, Zheng
AU  - Zhao Z
FAU - Zhang, Zheng
AU  - Zhang Z
FAU - Zhang, Qian
AU  - Zhang Q
FAU - He, Zhi-song
AU  - He ZS
FAU - Jin, Jie
AU  - Jin J
FAU - Zhou, Li-qun
AU  - Zhou LQ
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage
MH  - Carcinoma, Renal Cell/*drug therapy/pathology
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indoles/*administration & dosage
MH  - Kidney Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Pyrroles/*administration & dosage
MH  - Sunitinib
MH  - Young Adult
EDAT- 2013/08/09 06:00
MHDA- 2014/03/22 06:00
CRDT- 2013/08/09 06:00
PHST- 2013/08/09 06:00 [entrez]
PHST- 2013/08/09 06:00 [pubmed]
PHST- 2014/03/22 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2013;126(15):2826-9.